Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | PHASE1 | COMPLETED | 79 | — | — | Mar 19, 2021 | Sep 30, 2024 | Dec 27, 2024 | 18 | United States, Israel +1 |
Incidence of treatment emergent adverse events with CM-24 and nivolumab in adults with selected recurrent or metastatic solid tumors
Incidence of treatment emergent adverse events with CM-24 is used in combination with nivolumab and gemcitabin/nab-paclitaxel or Nal-IRI/5-FU/LV in adults with advanced metastatic pancreatic cancer
This is an exploratory randomized sub-study with the objective of estimating the efficacy of CM24 and nivolumab with chemotherapy (Nal-IRI/5-FU/LV or gemcitabine/ nab-paclitaxel) and chemotherapy only (Nal- IRI/5-FU/LV or gemcitabine/nab-paclitaxel) as measured by overall survival.
| Arm | Type | Description |
|---|---|---|
| Part A- Dose escalation of CM24 in combination with nivolumab | EXPERIMENTAL | - |
| Part C- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine | EXPERIMENTAL | - |
| Part C- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV | EXPERIMENTAL | - |
| Part D- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine | EXPERIMENTAL | - |
| Part D- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV | EXPERIMENTAL | - |
| Part D- Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine | ACTIVE_COMPARATOR | - |
| Part D- Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CM-24 and Nivolumab - Dose Escalation | DRUG | Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors |
| CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion | DRUG | Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer |
| CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion | DRUG | Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer |
| Nivolumab, Nab paclitaxel and Gemcitabine - Expansion | DRUG | Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer |
| Nivolumab and Nal-IRI/5-FU/LV - Expansion | DRUG | Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer |
Inclusion Criteria: 1. Part A: Previously treated subjects with recurrent and/or metastatic NSCLC, pancreatic cancer, ovarian cancer, papillary thyroid cancer, colorectal adenocarcinoma and melanoma with documented progression/intolerance following at least one previous therapy (and not more than 2...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |